Apellis, CHMP
Apellis: CHMP Once Again Recommends Against Syfovre
The CHMP initially adopted a negative opinion in January after finding it was unable to establish a positive balance of benefits and risks for Syfovre, but Apellis sought a re-examination and was able to submit new data in support of its application following an unrelated court ruling in Europe.
Europe's CHMP turns down Apellis' pegcetacoplan appeal, endorses new drugs from Pfizer, ImmunoGen and Henlius
Amid a parade of regulatory endorsements in Europe, Apellis Pharmaceuticals’ ophthalmology prospect pegcetacoplan has been left in the cold once again. | Europe’s Committee for Medicinal Products for Human Use has confirmed its negative stance on pegcetacoplan in geographic atrophy,
Apellis Pharmaceuticals (APLS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
Investor's Business Daily on MSN1d
Apellis Stock Hammered After Eye Drug Gets A Third European RejectionEuropean regulators rejected Apellis Pharmaceuticals' embattled eye drug, Syfovre, and Apellis stock tumbled to a month-low.
The decision against Syfovre’s approval follows efforts by Apellis to have reviewers reevaluate clinical evidence multiple times and, according to an analyst, will lead to a restructuring of the ...
Analyst Derek Archila of Wells Fargo assigned a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), retaining the price ...
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)’s two primary revenue generating treatments EMPAVELI and SYFOVRE are primarily targeted towards people with eye diseases. The firm is also trying to ...
and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email ...
Syfovre, also known as pegcetacoplan, is a medicine used to treat geographic atrophy, which is the advanced form of dry age-related macular degeneration. Geographic atrophy can cause ...
The firm's stance comes ahead of the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) expected final opinion on the approval of Apellis's drug pegcetacoplan ...
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)'s two primary revenue generating treatments EMPAVELI and SYFOVRE are primarily targeted towards people with eye diseases. The firm is also trying to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback